{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:45:29Z","timestamp":1792889129752,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Huntington's disease (HD) is characterised by a triad of cognitive, behavioural, and motor symptoms which lead to functional decline and loss of independence. With potential disease-modifying therapies in development, there is interest in accurately measuring HD progression and characterising prognostic variables to improve efficiency of clinical trials. Using the large, prospective Enroll-HD cohort, we investigated the relative contribution and ranking of potential prognostic variables in patients with manifest HD. A random forest regression model was trained to predict change of clinical outcomes based on the variables, which were ranked based on their contribution to the prediction. The highest-ranked variables included novel predictors of progression\u2014being accompanied at clinical visit, cognitive impairment, age at diagnosis and tetrabenazine or antipsychotics use\u2014in addition to established predictors, cytosine adenine guanine (CAG) repeat length and CAG-age product. The novel prognostic variables improved the ability of the model to predict clinical outcomes and may be candidates for statistical control in HD clinical studies.<\/jats:p>","DOI":"10.3389\/fneur.2021.678484","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T11:42:25Z","timestamp":1621597345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Ranking the Predictive Power of Clinical and Biological Features Associated With Disease Progression in Huntington's Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Naghmeh","family":"Ghazaleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Schobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Wijeratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington's disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J Rare Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/mds.26011","article-title":"Diagnostic criteria for Huntington's disease based on natural history","volume":"29","author":"Reilmann","year":"2014","journal-title":"Mov Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajhg.2015.12.018","article-title":"The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease","volume":"98","author":"Keum","year":"2016","journal-title":"Am J Hum Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1474-4422(14)70238-8","article-title":"Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study","volume":"13","author":"Paulsen","year":"2014","journal-title":"Lancet Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","article-title":"Cognitive impairment in Huntington disease: diagnosis and treatment","volume":"11","author":"Paulsen","year":"2011","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fnagi.2014.00078","article-title":"Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study","volume":"6","author":"Paulsen","year":"2014","journal-title":"Front Aging Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.31887\/DCNS.2007.9.2\/arosenblatt","article-title":"Neuropsychiatry of Huntington's disease","volume":"9","author":"Rosenblatt","year":"2007","journal-title":"Dialogues Clin Neurosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington's disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/mds.27122","article-title":"Design optimization for clinical trials in early-stage manifest Huntington's disease","volume":"32","author":"Frost","year":"2017","journal-title":"Mov Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2019.2368","article-title":"Association of CAG repeats with long-term progression in huntington disease","volume":"76","author":"Langbehn","year":"2019","journal-title":"JAMA Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12859-017-1650-8","article-title":"Intervention in prediction measure: a new approach to assessing variable importance for random forests","volume":"18","author":"Epifanio","year":"2017","journal-title":"BMC Bioinformatics."},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17849\/insm-47-01-31-39.1","article-title":"Random forest","volume":"47","author":"Rigatti","year":"2017","journal-title":"J Insur Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","article-title":"Motor, cognitive, and functional declines contribute to a single progressive factor in early HD","volume":"89","author":"Schobel","year":"2017","journal-title":"Neurology."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/currents.hd.8060298fac1801b01ccea6acc00f97cb","article-title":"Medication use in early-HD participants in track-hd: an investigation of its effects on clinical performance","volume":"8","author":"Keogh","year":"2016","journal-title":"PLoS Curr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JHD-130071","article-title":"Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study","volume":"2","author":"Dorsey","year":"2013","journal-title":"J Huntingtons Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1212\/WNL.0000000000005817","article-title":"Evaluating depression and suicidality in tetrabenazine users with Huntington disease","volume":"91","author":"Schultz","year":"2018","journal-title":"Neurology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1212\/WNL.0000000000003661","article-title":"Substance abuse may hasten motor onset of Huntington disease: evaluating the Enroll-HD database","volume":"88","author":"Schultz","year":"2017","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1002\/mds.28062","article-title":"Hypertension is associated with an earlier age of onset of huntington's disease","volume":"35","author":"Schultz","year":"2020","journal-title":"Mov Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ana.25007","article-title":"Body weight is a robust predictor of clinical progression in Huntington disease","volume":"82","author":"van","year":"2017","journal-title":"Ann Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fgene.2018.00137","article-title":"Dose response and prediction characteristics of a methylation sensitive digital PCR assay for cigarette consumption in adults","volume":"9","author":"Philibert","year":"2018","journal-title":"Front Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2105-8-25","article-title":"Bias in random forest variable importance measures: illustrations, sources and a solution","volume":"8","author":"Strobl","year":"2007","journal-title":"BMC Bioinformatics."},{"key":"B25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3934\/publichealth.2019.4.405","article-title":"Supervised machine learning models applied to disease diagnosis and prognosis","volume":"6","author":"Mariani","year":"2019","journal-title":"AIMS Public Health."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMp1606181","article-title":"Predicting the future\u2014big data, machine learning, and clinical medicine","volume":"375","author":"Obermeyer","year":"2016","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"eabc2888","DOI":"10.1126\/scitranslmed.abc2888","article-title":"Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease","volume":"12","author":"Rodrigues","year":"2020","journal-title":"Sci Transl Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci Transl Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-019-0863-0","article-title":"Clinical risk prediction with random forests for survival, longitudinal, and multivariate (RF-SLAM) data analysis","volume":"20","author":"Wongvibulsin","year":"2019","journal-title":"BMC Med Res Methodol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.678484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T11:42:27Z","timestamp":1621597347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.678484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":30,"alternative-id":["10.3389\/fneur.2021.678484"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.678484","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"article-number":"678484"}}